OakChart

Corbus Pharmaceuticals Holdings Inc

CRBPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 8:07 AM ET

4.00+0.07 (1.78%)
2026-11-11 14:32 CET
Market cap
76.01 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-116.31 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-6.09
P/E
-
Compare

Price

CRBP against its 20, 50 and 200-day averages
2050200beatmiss
2.505.007.5010.0012.504.2M8.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRBPclose 4.0020-day 3.9950-day 5.99200-day 8.414.00

76.8% under 17.24 on 30 Oct 2025. Last 15 sessions, 60.9% high to low

Profile

CRBP
52-week range, 12% of the way up
2.8112.88

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

IndexRUT
Employees36
IPOOct 27, 2014
Beta2.80
ATR, 14d0.44
Rel volume0.08
Short float18.69%
Insider own10.22%
Inst own61.79%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap77.36M
Enterprise Value-34.07M
Income-116.31M
Sales0.00M
Book/sh4.11
Cash/sh5.96
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees36
IPOOct 27, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.97
P/C0.67
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.40
Current Ratio3.40
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.09
EPS next Y-5.25
EPS next Q-1.43
EPS this Y0.71%
EPS next Y10.46%
EPS next 5Y1.77%
EPS past 3/5Y16.56% 32.70%
Sales past 3/5Y- -
EPS Y/Y TTM-10.49%
Sales Y/Y TTM-
EPS Q/Q4.47%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-42.24% -100.00%

Ownership

Insider Own10.22%
Insider Trans-18.52%
Inst Own61.79%
Inst Trans-2.72%
ROA-100.09%
ROE-131.50%
ROIC-132.27%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.30%
SMA50-33.23%
SMA200-52.46%
Trades-

Technical

Shs Outstand20.61M
Shs Float17.36M
Short Float18.69%
Short Ratio3.05
Short Interest3.24M
52W High12.88 -68.95%
52W Low2.81 42.35%
Volatility18.73% 10.50%
ATR (14)0.44
RSI (14)41.26
Beta2.80
Rel Volume0.08
Avg Volume1.06M
Volume4,115

Performance

Perf Week12.04%
Perf Month-16.32%
Perf Quarter-60.32%
Perf Half Y-67.08%
Perf YTD-50.86%
Perf Year-61.61%
Perf 3Y23.08%
Perf 5Y-87.30%
Perf 10Y-97.72%
Recom1.00
Target Price32.52
Prev Close3.93
Price4.00
Change %1.78%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 29, 2026InitiatedGGuggenheimBuy$45+1,025.0%
Jul 30, 2025ResumedRB. Riley SecuritiesBuy$28+600.0%
Feb 28, 2025InitiatedWWilliam BlairOutperform
Dec 02, 2024InitiatedPPiper SandlerOverweight
Jul 30, 2024InitiatedWWedbushOutperform$85+2,025.0%
Jul 22, 2024ResumedHH.C. WainwrightBuy$80+1,900.0%
Jun 26, 2024InitiatedRB. Riley SecuritiesBuy$85+2,025.0%
Jun 03, 2024ReiteratedOOppenheimerOutperform$60 → $80+1,900.0%
May 13, 2024InitiatedRRBC Capital MktsOutperform$77+1,825.0%
Mar 06, 2024UpgradeJJefferiesHold → Buy$4 → $46+1,050.0%

Peers

Mkt cap
TickerCompanyMkt cap
WHWKWhitehawk Therapeutics Inc181.75M
KYNBKyntra Bio Inc14.46M
PYXSPyxis Oncology Inc194.96M
STROSutro Biopharma Inc168.63M
MGNXMacrogenics Inc154.15M
AKTSAktis Oncology Inc973.90M
ALTAltimmune Inc389.03M
SKYESkye Bioscience Inc3.98M
VKTXViking Therapeutics Inc3.74B
ARTLArtelo Biosciences Inc1.22M

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cormorant Asset Management, LPFormer 10% OwnerOct 29 '26Sale4.10425,0001,742,7551,919,971Nov 02 04:05 PM
Ben YongDirectorSep 14 '26Sale7.842,00015,6839,383Sep 15 04:59 PM
Saxena Nishant CChief Business OfficerAug 11 '26Buy9.632,60025,03677,900Aug 12 04:30 PM
Cohen YuvalChief Executive OfficerAug 07 '26Sale10.0817,000171,396157,316Aug 10 04:30 PM
Moran Sean F.Chief Financial OfficerAug 07 '26Sale10.0812,000120,97184,694Aug 10 04:30 PM
Stifel, Nicolaus & Company, InOfficerAug 07 '26Proposed Sale10.0812,000120,971Aug 07 04:23 PM
Stifel, Nicolaus & Company, InOfficerAug 07 '26Proposed Sale10.0817,000171,396Aug 07 04:04 PM
Smethurst DominicOfficerJul 27 '26Proposed Sale9.2023,025211,818Jul 27 04:06 PM
Kung WinstonDirectorJun 10 '26Sale7.912,02616,03312,140Jun 11 04:30 PM
Altmeyer AnneDirectorJun 10 '26Sale7.912,41219,0887,579Jun 11 04:30 PM
Jenkins John KennethDirectorJun 10 '26Sale7.914,80037,9863,833Jun 11 04:30 PM
Saxena Nishant CChief Business OfficerJun 03 '26Buy7.589,00068,22075,300Jun 03 05:36 PM
Saxena Nishant CChief Business OfficerJun 02 '26Buy7.334,50032,99866,300Jun 03 05:36 PM
Smethurst DominicChief Medical OfficerMar 02 '26Sale8.306,09750,60189,790Mar 04 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
IWCiShares Micro-Cap ETFAUM: 1.23B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 213.08M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.30B

News

latest 14 of 206
  • Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press) +11.65%
  • Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
  • Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November (GlobeNewswire) -19.89%
  • Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week 2026 (GlobeNewswire)
  • Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer (GlobeNewswire)
  • Loading…
  • Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data (InvestorsHub)
  • Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity (GlobeNewswire)
  • Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity (GlobeNewswire)
  • Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
  • Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
  • Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity (GlobeNewswire) +5.38%
  • Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-1.810-1.273-1.8100.001.6710
2026Q22026-08-06-1.810-1.259-1.8050.000.0010
2026Q12026-05-12-1.230-1.221-1.2280.000.008
2025Q42026-03-09-1.250-1.518-1.2470.001.6710
2025Q32025-11-12-1.900-1.657-1.8970.000.0010
2025Q22025-08-05-1.440-1.496-1.4430.000.009
2025Q12025-05-06-1.390-1.223-1.3910.000.009
2024Q42025-03-11-0.780-1.265-0.7830.000.0010
2024Q32024-11-07-1.150-0.952-1.1470.000.008
2024Q22024-08-06-0.900-1.188-0.9040.000.006
2024Q12024-05-07-0.830-1.090-0.8300.00-2
2023Q42024-03-12-1.810-2.155-1.813--2
2023Q32023-11-07-2.270-2.060-2.273--1
2023Q22023-08-08-2.050-3.100-2.053--1
2023Q12023-05-09-4.240-4.090-4.2440.000.001
2022Q42023-03-07-2.610-2.100-2.6080.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-33.600-32.340-33.54736.1437.27
2020FY-42.600-48.180-42.7233.944.77
2021FY-11.100-12.375-11.1330.881.12
2022FY-10.150-9.500-10.1540.000.00
2023FY-10.310-10.655-10.30736.14-
2024FY-3.680-4.362-3.6840.000.00
2025FY-5.900-6.672-5.9000.001.67
2026FY--5.858--2.00
2027FY--5.246--3.02
2028FY--5.592--4.18
2029FY--4.107--67.54
2030FY--0.789--210.94

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104000.000.000.00
2026Q4S2026-09-304000.000.000.00
2026Q4S2026-08-065000.000.000.00
2026Q4S2026-05-125000.000.000.00
2026Q4S2026-04-164000.000.000.00
2026Q4S2026-04-015000.000.000.00
2026Q4S2026-03-094000.000.000.00
2026Q4S2025-11-124000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4R2026-11-10101-2.00-2.00-2.00
2026Q4R2026-10-20100-0.99-0.99-0.99
2026Q4R2026-08-20110-0.99-0.99-0.99
2026Q4R2026-08-06210-1.09-1.19-0.99

Estimate history

EPS, annual-19.5-29.301-33.547-42.723-11.133-10.154-10.307-3.684-5.897-6.092
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.147-0.783-1.391-1.443-1.897-1.247-1.228-1.805-1.812
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.444.82236.1443.9370.88200000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.8531.9082.1563.2954.1744.1714.42412.17917.61220.607
Period201720182019202020212022202320242025MRQ
Shares, quarterly12.17912.17912.23312.25412.53517.61217.73918.67120.607
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.883.9436.144.82
Cost of Goods Sold Incl. D&A0.000.230.600.641.491.64---
Gross Profit0.00-0.23-0.60-0.64-1.49-0.76---
Selling, General and Administrative Excl. Other121.1485.0848.1244.4433.3555.23125.05116.6061.08
Research and Development103.6570.0932.2231.1716.1436.4598.2794.1948.61
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-121.28-85.31-48.72-45.08-34.84-55.99-122.81-81.69-56.75
Interest Expense-0.001.872.922.131.831.030.020.01
Unusual Expense--1.100.000.004.90-0.660.250.000.19
Net Income Before Taxes-116.31-78.54-40.21-44.60-42.35-58.44-124.97-76.04-55.67
Income Taxes0.000.000.000.000.00-12.80-13.70-4.580.00
Consolidated Net Income-116.31-78.54-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Net Income From Continuing Operations-116.31-78.54-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Net Income-116.31-78.54-40.21-44.60-42.35-45.64-111.27-71.45-55.67
EPS (Recurring)-5.58-5.96-3.68-10.31-9.33-11.25-42.66-33.55-29.23
EPS (Basic, Before Extraordinaries)-6.09-5.90-3.68-10.31-10.15-11.13-42.72-33.55-29.30
EPS (Diluted)-6.09-5.90-3.68-10.31-10.15-11.13-42.72-33.55-29.30
EBITDA--85.08-48.12-44.44-33.35-54.35-121.12-80.46-56.25
Non-Operating Income (Expense)4.975.6710.383.40-0.48-1.28-0.885.671.27
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-6.296.143.475.726.9212.4611.987.61
Price To Sales Ratio-----85.8824.819.6569.03
Gross Margin------85.92---
Operating Margin------6,350.09-3,119.20-226.01-1,176.78
Net Margin------5,176.38-2,826.08-197.69-1,154.48
Shares Outstanding20.6117.6112.184.424.174.173.302.161.91
Market Capitalization76.0176.01143.7226.7213.8477.10123.57353.11334.33

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.050.050.050.100.100.100.15
Gross Profit0.00-0.05-0.05-0.05-0.10-0.10-0.10-0.15
Selling, General and Administrative Excl. Other38.8236.1424.2521.9224.3219.0519.6812.46
Research and Development34.2531.1819.8218.4120.8615.1915.648.79
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-38.82-36.19-24.30-21.97-24.42-19.15-19.77-12.61
Interest Expense-0.000.000.000.000.000.00-
Unusual Expense-0.000.000.000.000.000.000.00
Net Income Before Taxes-37.75-35.04-22.97-20.55-23.34-17.66-16.98-9.53
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-37.75-35.04-22.97-20.55-23.34-17.66-16.98-9.53
Net Income From Continuing Operations-37.75-35.04-22.97-20.55-23.34-17.66-16.98-9.53
Net Income-37.75-35.04-22.97-20.55-23.34-17.66-16.98-9.53
EPS (Recurring)-1.81-1.81-1.23-1.25-1.90-1.44-1.39-0.78
EPS (Basic, Before Extraordinaries)-1.81-1.81-1.23-1.25-1.90-1.44-1.39-0.78
EPS (Diluted)-1.81-1.81-1.23-1.25-1.90-1.44-1.39-0.78
EBITDA--36.14-24.25-21.92-24.32-19.05-19.68-12.46
Non-Operating Income (Expense)1.071.151.331.411.071.492.803.08
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.811.921.431.581.561.711.63
Shares Outstanding20.6118.6717.7417.6112.5312.2512.2312.18
Market Capitalization76.01173.79166.55142.88155.0384.4364.95143.72

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments163.94149.3521.1059.3997.8485.7831.7541.7562.70
Short Term Receivables1.500.000.000.000.002.582.680.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.513.632.450.792.373.713.722.492.81
Total Current Assets166.95152.9823.5560.18100.2092.0738.1544.2465.50
Net Property, Plant & Equipment1.242.524.045.507.009.3210.902.711.43
Total Investments and Advances0.000.390.480.480.480.670.000.000.00
Intangible Assets0.000.00-------
Other Assets0.000.000.210.160.050.230.080.040.04
Total Assets168.19155.8828.2766.31107.73102.2949.1446.9966.98
Short Term Debt Incl. Current Port. of LT Debt1.631.6117.654.435.001.711.350.390.34
Accounts Payable2.214.793.182.171.787.3811.096.353.13
Other Current Liabilities16.845.4311.076.0410.2322.8022.4511.354.74
Total Current Liabilities20.6911.8231.8912.6417.0131.9034.8918.098.20
Long Term Debt0.001.633.2420.6621.5925.128.100.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.040.020.020.000.001.380.99
Total Liabilities20.6913.4535.1833.3238.6257.0242.9819.479.19
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity147.50142.43-6.9032.9969.1145.276.1627.5257.78
Total Shareholders Equity147.50142.43-6.9032.9969.1145.276.1627.5257.78
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity147.50142.43-6.9032.9969.1145.276.1627.5257.78
Total Liabilities & Stockholders Equity168.19155.8828.2766.31107.73102.2949.1446.9966.98
Book Value Per Share8.3811.69-1.567.9116.5613.742.8614.4231.18
Tangible Book Value Per Share8.3811.69-1.567.9116.5613.742.8614.4231.18
Full-Time Employees3628193341761417747
Price to Book Ratio0.960.9585.910.331.122.7357.3512.1511.15
Return on Assets-48.47-43.67-94.31-48.66-43.46-146.95-148.66-97.70-76.41
Return on Equity-54.18-59.34-341.98-82.95-79.80-432.68-424.29-130.52-97.21
Return on Invested Capital-53.24-27.91--78.93-50.32-158.06-501.26-202.27-56.11
Quick Ratio8.0712.940.744.765.892.891.092.457.98
Current Ratio8.0712.940.744.765.892.891.092.457.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--78.54-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Depreciation-0.230.590.641.491.641.691.230.49
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-4.693.403.777.3411.5113.0912.038.10
Funds from Operations--73.61-36.22-40.19-33.52-32.49-96.48-58.20-47.08
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-9.12-5.584.09-4.02-15.70-3.2012.4817.01
Cash from Operating Activities--64.49-41.79-36.10-37.54-48.18-99.69-45.72-30.07
Capital Expenditures--0.010.000.00-0.01-0.05-0.48-2.74-2.30
Net Assets From Acquisitions-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.000.000.000.010.020.000.00-
Purchase or Sale of Investments--1.63-121.3135.6430.08-73.390.000.000.00
Purchase of Investments--163.09-180.80-33.88-86.34-87.270.000.000.00
Sale Or Maturity of Investments-161.4659.4969.53116.4213.880.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--1.64-121.3135.6430.07-73.42-0.48-2.74-2.30
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-77.43182.060.050.0060.77136.1638.1111.36
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-77.43182.060.050.0060.77136.1638.1111.36
Proceedsfrom Stock Options-77.43182.060.050.0060.77136.1638.1111.36
Issuance or Reduction of Debt, Net-0.00-15.48-2.87-0.530.0618.710.360.06
Change in Long Term Debt-0.00-15.18-2.450.330.9818.760.360.06
Issuance of Long Term Debt-0.000.000.371.830.9818.760.960.49
Reduction of Long Term Debt-0.00-15.18-2.82-1.500.000.00-0.61-0.43
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-77.43166.58-2.82-0.5360.82154.8738.4611.42
Net Change in Cash-11.293.47-3.28-8.00-60.7854.70-10.00-20.95
Free Cash Flow--64.50-41.79-36.10-37.56-48.24-100.17-48.46-32.37

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments115.34117.94138.60163.94104.27116.88
Short Term Receivables-0.000.001.501.501.50
Inventories-0.000.000.000.000.00
Other Current Assets3.614.814.961.511.804.45
Total Current Assets118.95122.75143.57166.95107.57122.83
Net Property, Plant & Equipment3.573.850.911.241.561.88
Total Investments and Advances0.390.390.000.000.390.39
Intangible Assets-0.000.000.000.000.00
Other Assets-0.000.000.000.000.00
Total Assets122.90126.99144.48168.19109.51125.08
Short Term Debt Incl. Current Port. of LT Debt0.731.001.211.631.741.70
Accounts Payable4.075.250.432.212.743.99
Other Current Liabilities30.1715.2316.5016.8412.587.65
Total Current Liabilities34.9721.4818.1420.6917.0613.33
Long Term Debt3.183.270.000.000.310.76
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities38.1424.7518.1420.6917.3714.09
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity84.76102.24126.34147.5092.15110.99
Total Shareholders Equity84.76102.24126.34147.5092.15110.99
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity84.76102.24126.34147.5092.15110.99
Total Liabilities & Stockholders Equity122.90126.99144.48168.19109.51125.08
Book Value Per Share4.115.487.128.387.359.06
Tangible Book Value Per Share-5.487.128.387.359.06
Full-Time Employees---36--
Price to Book Ratio0.961.321.121.111.400.66
Return on Assets-100.09-80.85-59.44-48.47-49.34-41.83
Return on Equity-131.50-95.58-66.70-54.18-55.65-49.00
Return on Invested Capital-42.93-33.21-18.18-13.94-25.25-15.80
Quick Ratio-5.717.928.076.319.21
Current Ratio3.405.717.928.076.319.21

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--35.04-22.97-20.55-23.34-17.66
Depreciation-0.050.050.050.050.05
Other Funds (Non Cash)-1.591.650.751.580.89
Funds from Operations--33.40-21.27-19.76-21.71-16.72
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-3.77-4.303.836.160.12
Cash from Operating Activities--29.63-25.57-15.92-15.55-16.60
Capital Expenditures--0.01-0.01-0.010.000.00
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-18.2722.46-57.1419.6417.74
Purchase of Investments--8.70-10.73-90.02-17.84-17.62
Sale Or Maturity of Investments-26.9633.1932.8837.4835.37
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities-18.2622.45-57.1519.6417.74
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-9.070.0074.582.850.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-9.070.0074.582.850.00
Proceedsfrom Stock Options-9.070.0074.582.850.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.00
Cash from Financing Activities-9.070.0074.582.850.00
Net Change in Cash--2.29-3.121.516.941.14
Free Cash Flow--29.63-25.58-15.93-15.55-16.60

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.69%3.2M17.4M922.49K
2026-10-1515.64%2.7M17.4M803.22K
2026-09-3017.60%3.1M17.4M704.81K
2026-09-1515.89%2.8M17.4M667.58K
2026-08-3113.00%2.2M17.3M436.12K
2026-08-1412.45%2.1M17.3M493.96K
2026-07-3113.25%2.3M17.4M488.78K
2026-07-1512.61%2.1M16.6M503.84K
2026-06-3011.70%1.9M16.6M479.30K
2026-06-159.50%1.6M16.6M413.65K
2026-05-299.25%1.5M16.5M379.29K
2026-05-157.23%1.2M16.6M247.89K
2026-04-308.79%1.4M16.0M220.20K
2026-04-158.40%1.3M16.0M194.23K
2026-03-317.75%1.2M15.6M188.52K
2026-03-138.49%1.3M15.6M196.69K
2026-02-278.51%1.3M15.5M274.83K
2026-02-138.47%1.3M15.5M291.98K
2026-01-308.42%1.3M15.9M395.86K
2026-01-158.27%1.3M15.9M452.08K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.001.004.000.000.0000.000.000.964-0.0180.001
call2.500.002.200.006.9620.000.000.839-0.0350.002
call4.000.052.000.302.06140.0036.000.567-0.0330.003
call5.000.100.500.101.7841,0319380.251-0.0190.002
call6.000.002.000.002.4730.000.000.201-0.0230.002
call7.500.002.000.043.21689.000.000.169-0.0270.002
call10.000.000.150.153.70611.000.000.109-0.0230.001
call12.500.002.000.134.2966.000.000.099-0.0250.001
call15.000.002.000.004.7560.000.000.093-0.0260.001
put1.000.000.100.006.0890.000.00-0.042-0.0150.001
put2.500.000.750.054.38840.000.00-0.161-0.0350.002
put4.000.000.850.003.1840.000.00-0.433-0.0320.003
put5.000.002.451.855.7854.000.00-0.699-0.0260.002
put6.001.004.000.007.7510.000.00-0.799-0.0220.002
put7.502.004.904.008.2172.000.00-0.831-0.0260.002
put10.005.008.006.509.6320.000.00-0.891-0.0220.001
put12.507.0011.000.0014.7210.000.00-0.901-0.0230.001
put15.009.1013.500.0015.2530.000.00-0.907-0.0240.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-11-02SCHEDULE 13G/ASEC
2026-10-29SCHEDULE 13G/ASEC
2026-10-158-KCurrent report2026-10-15SEC
2026-09-30SCHEDULE 13GSEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-16SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07424B5SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-043Initial statement of beneficial ownership of securities2026-08-03SEC
2026-07-27SCHEDULE 13GSEC
2026-07-27144Filing for proposed sale of securities under Rule 144.SEC
2026-07-068-KCurrent report2026-07-02SEC
2026-06-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-05-29S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-268-KCurrent report2026-05-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.74M1
2026-090015.68K1
2026-0825.04K1292.37K2
2026-070000
2026-06101.22K273.11K3
2026-050000
2026-040000
2026-030050.60K1
2026-0200196.91K5
2026-010000
2025-1200344.01K1
2025-110000

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC9.38%
BlackRock, Inc.7.18%
Aberdeen Group plc7.13%
VANGUARD CAPITAL MANAGEMENT LLC4.11%
Jones Hill Capital LP3.53%
Prosight Management, LP3.51%
GEODE CAPITAL MANAGEMENT, LLC2.33%
Stonepine Capital Management, LLC2.29%
ADAR1 Capital Management, LLC2.28%
DIADEMA PARTNERS LP1.63%

Funds

Fund% owned
abrdn Healthcare Investors4.20%
abrdn Life Sciences Investors2.93%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.88%
iShares Russell 2000 ETF2.20%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Small Cap Index Fund0.97%
iShares Russell 2000 Value ETF0.85%
VANGUARD RUSSELL 2000 INDEX FUND0.49%
Dimensional U.S. Small Cap ETF0.32%
iShares Micro-Cap ETF0.30%

OakChart. CRBP. Cached 15 minutes.